Tuesday, February 23, drug companies said that the United States can expect to see a total of 240 million doses of the COVID-19 vaccine by the end of March.
Pfizer and Moderna — the two companies with COVID-19 vaccines authorized for emergency use in the United States — have pledged to make a combined total of 220 million doses available for shipment by the end of March.
Meanwhile, Johnson & Johnson, which could secure emergency use authorization for its COVID-19 vaccine from the US Food and Drug Administration later this week, has pledged to make 20 million doses available in the same time frame.
According to Dr. Richard Nettles, J&J’s Vice President of Medical Affairs, “If the emergency use authorization is received this week, we hope to contribute to ending this pandemic as soon as possible.”
Executives from each of the vaccine makers, along with executives from AstraZeneca and Novavax, testified before the House Committee on Energy and Commerce Subcommittee on Oversight and Investigations on Tuesday.
A fourth COVID-19 vaccine could become available in the US in April when AstraZeneca could secure FDA authorization of its vaccine. Dr. Ruud Dobber, the Executive Vice President and President of AstraZeneca’s biopharmaceuticals business unit, said the company will immediately release 30 million doses upon authorization of the vaccine and up to 50 million doses by the end of April.